CDC and FDA Warn Dozens Poisoned by Contaminated IV Glutathione
CDC and FDA warn contaminated IV glutathione from three Texas compounding pharmacies sickened dozens, with three hospitalized and one in intensive care.
PepNews
WIRED Tests Find NYC Bodega Peptides Contained No Active Ingredient
Independent lab testing commissioned by WIRED found peptide vials sold at NYC bodegas labeled as BPC-157 contained no detectable active ingredient.
Six Peptides Await FDA Rulemaking After PCAC Vote
PCAC recommended six peptides for the FDA's 503A Bulks List, but formal rulemaking must be completed before compounding pharmacies can legally prepare them.
Counterfeit Retatrutide Caused Torn Esophagus, TGA Testing Reveals
TGA testing found a counterfeit retatrutide product contained undeclared semaglutide at 8x normal dose, causing a patient's torn esophagus.
Lilly, FDA Clash in Seventh Circuit Over Retatrutide Classification
Oral arguments September 24 will determine whether retatrutide gets 12 or 5 years of data exclusivity, with major implications for the obesity drug pipeline.
Fifth Circuit Affirms FDA GLP-1 Delisting, Restricts Compounding
The Fifth Circuit upheld FDA's removal of semaglutide and tirzepatide from the shortage list, closing a key legal pathway for compounded GLP-1 production.
Thai FDA Seizes 52M Baht in Unregistered Peptide Injections
Thai authorities seized unregistered peptide injection products worth over 52 million baht from a Nonthaburi house, the second major peptide crackdown in 2026.
Smithsonian Magazine Investigates Peptide Industry’s Regulatory Gaps
Smithsonian Magazine examines how peptides like BPC-157 and TB-500 grew into a parallel healthcare system outside FDA oversight, highlighting regulatory gaps and consumer risks.
Seventh Circuit Sets Sept. 24 Arguments in Retatrutide Biologics Case
The Seventh Circuit will hear oral arguments September 24 in Eli Lilly v. RFK Jr., a case that could determine whether retatrutide is classified as a biologic or conventional drug.
FDA Adverse Event Reports for Compounded GLP-1s Top 1,700
FDA logs over 1,700 adverse event reports for compounded GLP-1s as a JAMA study finds compounders altering formulations to dodge the agency's copying ban.
